Free tool
FAERS Monitor: Fluorescite
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021980 or its brand name (Fluorescite, Fluorescein Sodium). Reports on generic versions are filed under their own applications.
Reports
564
Serious
539
96% of reports
Hospitalization
154
Death reported
34
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea72
- anaphylactic shock56
- pruritus54
- dyspnoea52
- dizziness50
- vomiting49
- rash47
- loss of consciousness45
- visual acuity reduced37
- chest discomfort31
- urticaria31
- asthenia25
- blood pressure decreased23
- drug hypersensitivity23
- syncope22
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 7 |
| 2005 | 10 |
| 2006 | 7 |
| 2007 | 7 |
| 2008 | 14 |
| 2009 | 76 |
| 2010 | 23 |
| 2011 | 12 |
| 2012 | 15 |
| 2013 | 11 |
| 2014 | 26 |
| 2015 | 24 |
| 2016 | 30 |
| 2017 | 20 |
| 2018 | 22 |
| 2019 | 35 |
| 2020 | 56 |
| 2021 | 22 |
| 2022 | 28 |
| 2023 | 31 |
| 2024 | 39 |
| 2025 | 34 |
| 2026 | 15 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,595 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| anaphylactic shockSignal | 56 | 81.2 | 63.3 | 4,352 |
| visual acuity reducedSignal | 37 | 41.6 | 30.5 | 1,426 |
| loss of consciousnessSignal | 45 | 13.1 | 9.9 | 494 |
| blood pressure decreasedSignal | 23 | 12.9 | 8.7 | 242 |
| chest discomfortSignal | 31 | 11.3 | 8.0 | 282 |
| syncopeSignal | 22 | 8.2 | 5.4 | 133 |
| urticariaSignal | 31 | 6.9 | 4.9 | 152 |
| pruritusSignal | 54 | 5.2 | 4.1 | 184 |
| drug hypersensitivitySignal | 23 | 4.4 | 3.0 | 58 |
| rashSignal | 47 | 4.0 | 3.1 | 106 |
| vomitingSignal | 49 | 3.9 | 3.0 | 105 |
| dizzinessSignal | 50 | 3.7 | 2.9 | 100 |
| dyspnoeaSignal | 52 | 3.4 | 2.6 | 89 |
| nauseaSignal | 72 | 3.4 | 2.7 | 124 |
| astheniaSignal | 25 | 2.5 | 1.7 | 21 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.